Horizon Therapeutics Public Limited Company (HZNP) 은(는) 상장 기업입니다 헬스케어 섹터의 제약 산업에서 운영. 본사 소재지는 Dublin, Ireland. 현재 CEO는 Timothy P. Walbert.
HZNP 을(를) 보유 IPO 날짜 2011-07-28, 2,190 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $26.6B.
Horizon Therapeutics Public Limited Company is a biotechnology company focused on discovering, developing, and commercializing medicines for rare, autoimmune, and severe inflammatory diseases. The company operates through two segments—Orphan and Inflammation—with a portfolio of 12 medicines spanning rare diseases, gout, ophthalmology, and inflammatory conditions. Its marketed products include TEPEZZA for thyroid eye disease, KRYSTEXXA for gout, RAVICTI and PROCYSBI for rare metabolic disorders, ACTIMMUNE for chronic granulomatous disease, and several anti-inflammatory and pain management therapies such as PENNSAID, DUEXIS, RAYOS, and VIMOVO. Founded in 2005 and headquartered in Dublin, Ireland, Horizon maintains research and commercial operations across multiple locations in the United States, Germany, and internationally through strategic collaborations with biotechnology partners.
